CDT EQUITY INC. Operating Cash Flow
CDT EQUITY INC. (CDT) reported Operating Cash Flow of -$2.44 million for the 6-month period ending 2026-06-30, per its S-1 filed 2026-09-08.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-09-08
- CDT EQUITY INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$544.00K.
- CDT EQUITY INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$1.89M.
- CDT EQUITY INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$4.64M.
- CDT EQUITY INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$4.41M.
- CDT EQUITY INC. net cash provided by (used in) operating activities for fiscal 2023 was -$7.72M.
- CDT EQUITY INC. net cash provided by (used in) operating activities for fiscal 2022 was -$2.27M.
| Period end | Net Cash Provided by (Used in) Operating Activities 2 month | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$544.00K derived: S-1 6 month − 10-Q 3 month · filed 2026-09-08 | -$2.44M S-1 · filed 2026-09-08 | -$7.07M derived: sum of 3 quarters · filed 2026-09-08 | -$11.48M derived: sum of 4 quarters · filed 2026-09-08 | |||||
| 2026-03-31 | -$1.89M 10-Q · filed 2026-07-15 | -$6.53M derived: sum of 2 quarters · filed 2026-09-08 | -$10.94M derived: sum of 3 quarters · filed 2026-09-08 | -$13.52M derived: sum of 4 quarters · filed 2026-09-08 | |||||
| 2025-12-31 | -$4.64M derived: S-1 12 month − 10-Q 9 month · filed 2026-09-08 | -$9.05M derived: sum of 2 quarters · filed 2026-09-08 | -$11.63M derived: sum of 3 quarters · filed 2026-09-08 | -$15.55M S-1 · filed 2026-09-08 | |||||
| 2025-09-30 | -$4.41M derived: 10-Q 9 month − S-1 6 month · filed 2025-11-13 | -$6.99M derived: sum of 2 quarters · filed 2026-09-08 | -$10.92M 10-Q · filed 2025-11-13 | -$14.73M derived: sum of 4 quarters · filed 2026-09-08 | |||||
| 2025-06-30 | -$2.58M derived: S-1 6 month − 10-Q 3 month · filed 2026-09-08 | -$6.51M S-1 · filed 2026-09-08 | -$10.32M derived: sum of 3 quarters · filed 2026-09-08 | -$12.32M derived: sum of 4 quarters · filed 2026-09-08 | |||||
| 2025-03-31 | -$3.93M 10-Q · filed 2026-07-15 | -$4.33M 10-Q · filed 2025-05-15 | -$7.74M derived: sum of 2 quarters · filed 2026-09-08 | -$9.74M derived: sum of 3 quarters · filed 2026-09-08 | -$11.25M derived: sum of 4 quarters · filed 2026-09-08 | ||||
| 2024-12-31 | -$3.81M derived: S-1 12 month − 10-Q 9 month · filed 2026-09-08 | -$5.81M derived: sum of 2 quarters · filed 2026-09-08 | -$7.33M derived: sum of 3 quarters · filed 2026-09-08 | -$9.68M S-1 · filed 2026-09-08 | |||||
| 2024-09-30 | -$2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$3.51M derived: sum of 2 quarters · filed 2025-11-13 | -$5.87M 10-Q · filed 2025-11-13 | -$10.67M derived: sum of 4 quarters · filed 2025-11-13 | |||||
| 2024-06-30 | -$1.51M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2025-08-14 | -$3.87M 10-Q · filed 2025-08-14 | -$8.67M derived: sum of 3 quarters · filed 2025-08-14 | -$9.20M derived: sum of 4 quarters · filed 2025-08-14 | |||||
| 2024-03-31 | -$2.36M 10-Q/A · filed 2025-08-14 | -$7.16M derived: sum of 2 quarters · filed 2025-08-14 | -$7.68M derived: sum of 3 quarters · filed 2025-08-14 | -$8.11M derived: sum of 4 quarters · filed 2025-08-14 | |||||
| 2023-12-31 | -$4.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$5.33M derived: sum of 2 quarters · filed 2025-03-28 | -$5.75M derived: sum of 3 quarters · filed 2025-03-28 | -$7.72M 10-K · filed 2025-03-28 | |||||
| 2023-09-30 | -$524.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2024-11-14 | -$952.00K derived: sum of 2 quarters · filed 2024-11-14 | -$2.92M 10-Q · filed 2024-11-14 | -$3.80M derived: sum of 4 quarters · filed 2024-11-14 | |||||
| 2023-06-30 | -$428.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-14 | -$2.40M 10-Q/A · filed 2024-11-14 | -$1.22M 10-Q · filed 2023-08-14 | -$3.28M derived: sum of 3 quarters · filed 2024-11-14 | -$3.84M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-03-31 | -$1.97M 10-Q/A · filed 2024-11-14 | -$599.82K 10-Q · filed 2023-05-15 | -$2.85M derived: sum of 2 quarters · filed 2024-11-14 | -$3.42M derived: sum of 3 quarters · filed 2024-11-14 | -$3.54M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2022-12-31 | -$880.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2024-04-16 | -$1.45M derived: sum of 2 quarters · filed 2024-04-16 | -$1.57M derived: sum of 3 quarters · filed 2024-04-16 | -$2.27M 10-K · filed 2024-04-16 | -$1.31M 10-K · filed 2023-03-28 | ||||
| 2022-09-30 | -$566.60K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2023-11-21 | -$693.51K derived: sum of 2 quarters · filed 2023-11-21 | -$1.39M 10-Q/A · filed 2023-11-21 | -$929.01K 10-Q · filed 2022-11-07 | |||||
| 2022-06-30 | -$126.92K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$819.40K 10-Q · filed 2023-08-14 | |||||||
| 2022-03-31 | -$692.49K 10-Q · filed 2023-05-15 | ||||||||
| 2021-12-31 | -$6.00K 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |